CLL Videos

Videos

Optimal Frontline Treatment Regimens for Patients With Chronic Lymphocytic Leukemia

08/16/2023

Featuring Susan M. O'Brien, MD

Featuring Susan M. O'Brien, MD ...

At the 2023 EHA meeting in Frankfurt, Germany, Susan M. O'Brien, MD, provided insights into the latest frontline therapeutic options for patients with chronic lymphocytic leukemia.

At the 2023 EHA meeting in...

08/16/2023

Oncology

Videos

Analyzing Mechanisms of Pirtobrutinib Resistance Among Patients With CLL Pre-Treated With a Covalent BTK Inhibitor

07/10/2023

Featuring Jennifer Brown, MD

At the 2023 EHA Congress, Jennifer Brown, MD, presented study findings on mechanisms of resistance to pirtobrutinib among patients with chronic lymphocytic leukemia pre-treated with a covalent BTK inhibitor.

At the 2023 EHA Congress,...

07/10/2023

Oncology

Videos

Ibrutinib Dose Adjustments in the Frontline Treatment of Patients With CLL

06/22/2023

Featuring Kerry Anne Rogers, MD

Featuring Kerry Anne Rogers, MD ...

At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.

At the 2023 ASCO Annual Meeting...

06/22/2023

Oncology

Videos

Long-Term Outcomes of CAR T-Cell Therapy for Patients With Relapsed/Refractory CLL

06/21/2023

Featuring Emily C. Liang, MD

At the 2023 ASCO annual meeting, Emily C. Liang, MD, shared data on the long-term outcomes of patients with relapsed/refractory chronic lymphocytic leukemia treated with CD19-targeting CAR T-cell therapy.

At the 2023 ASCO annual meeting,...

06/21/2023

Oncology

Sponsored

Videos

Chronic Lymphocytic Leukemia: A Review of Unmet Needs in Prognostic Biomarker Testing

06/07/2023

M. Yair Levy, MD, Texas Oncology, discusses the importance of biomarker testing for patients with CLL, reviews unmet needs in prognostic biomarker testing and selection of therapies, and outlines clinical practice guidelines for high-risk...

M. Yair Levy, MD, Texas...

06/07/2023

Oncology

Videos

Treating a Patient With Unmutated IGHV, ATM-Deleted Chronic Lymphocytic Leukemia

03/27/2023

Talha Munir, MD, St. James's Hospital in Leeds, United Kingdom, highlights his treatment choices for the case of a 76-year-old patient with chronic lymphocytic leukemia.

Talha Munir, MD, St. James's...

03/27/2023

Oncology

Videos

Early MRD Clearance With Ibrutinib Plus Venetoclax Yields Sustained Clinical and MRD Responses in CLL

01/26/2023

Talha Munir, MD, discusses findings from an exploratory analysis of the phase 2 CLARITY trial, which showed that early MRD clearance with ibrutinib plus venetoclax yields sustained clinical and MRD responses in relapsed/refractory CLL.

Talha Munir, MD, discusses...

01/26/2023

Oncology

Videos

Ibrutinib Plus Venetoclax Induces High Rates of MRD Negativity in IGHV-Unmutated CLL

01/16/2023

Talha Munir, MD, discusses findings from an updated interim analysis of the FLAIR study at the 2022 ASH Annual Meeting & Exposition in New Orleans, LA.

Talha Munir, MD, discusses...

01/16/2023

Oncology

Videos

Role of Minimal Residual Disease in the Management of CLL: How Do We Use it and When?

11/15/2022

Othman Al-Sawaf, MD, provides insight into the best use of minimal residual disease in the management of patients with CLL, which he presented at the 2022 Lymphoma, Leukemia & Myeloma Congress.

Othman Al-Sawaf, MD, provides...

11/15/2022

Oncology

Videos

BTK Inhibitors vs BCL-2 Inhibitors as Frontline Therapy for Patients With CLL

11/14/2022

Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.

Asher Chanan-Khan, MD, argues in...

11/14/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology